Surveillance of Dysplasia in Inflammatory Bowel Disease: The Gastroenterologist-Pathologist Partnership
Cancer prevention in inflammatory bowel disease depends on the detection of precancerous dysplasia during scheduled screening and surveillance colonoscopy, but the detection and diagnosis of dysplasia remain challenging. In this article, we review the risks of cancer and dysplasia in ulcerative colitis and the current prevention recommendations, and through a sample case, we demonstrate an approach that involves an active partnership between the gastroenterologist or surgeon and pathologist. We address the challenge of management of polypoid lesions and incorporate new information about degree of inflammation as an additional risk of neoplasia in these patients.
⁎Department of Medicine, University of Chicago, Chicago, Illinois, USA
‡Department of Pathology, University of Chicago, Chicago, Illinois
Address requests for reprints to: David T. Rubin, MD, 5841 S Maryland Avenue, MC 4076, Chicago, Illinois 60637; fax: (773) 702-2182.
1 David T. Rubin is a consultant to Procter and Gamble Pharmaceuticals, Salix Pharmaceuticals, Prometheus Pharmaceuticals, Abbott Immunology, and Given Imaging and has served as a consultant to UCB Pharma and Shire. David T. Rubin has also received grant support from Proctor & Gamble Pharmaceuticals, Prometheus Pharmaceuticals, Given Imaging, and Biomerica and has served on the speaker’s bureaus of Proctor & Gamble Pharmaceuticals, Salix Pharmaceuticals, and Prometheus Pharmaceuticals.
ABSTRACT